Routine monitoring of hepatocellular carcinoma (HCC) can be postponed for 2-3 months in patients who are otherwise stable. 

• All patients being examined for the diagnosis and management of HCC must be screened for COVID-19. 
• Include ID specialists and pulmonologists in the multidisciplinary team (MDT) for HCC care. 
• Non-surgical treatment strategies are recommended in most cases. Percutaneous ethanol injection (PEI) can be a feasible option in low and middle income countries.
• Administration of oral tyrosine kinase inhibitors should be done to avoid nosocomial exposures related to receiving infusion regimens.
• Delaying transplant for resolution of COVID-19 is preferred approach.

Source: WGO guidance for patients with COVID-19 and liver disease. Available at: https://www.worldgastroenterology.org/UserFiles/file/COVID19/WGO_200601_DACYKBNRDVLBMMCleanCOVID19andLiverDisease.pdf?utm_source=WGO%20Website&utm_medium=Website&utm_campaign=COVID19Informationwebpage_COVID19_Management_LiverDisease